Abstract
In SPARCL, first vascular event was reduced from 687 for placebo to 530 for atorvastatin (hazard ratio [HR] 0.74; p<0.001), with significant reductions in stroke or TIA, coronary events, and revascularization procedures. Here we describe treatment effects on total (first and subsequent) vascular
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
